21 results found.

Hodgkin's Disease Clinical Trial using Gemcitabine; Fludarabine; Melphalan; Antithymocyte Globulin; Allogeneic Stem Cell Infusion; Tacrolimus; Filgrastim (G-CSF); Methotrexate

M.D. Anderson Cancer Center - Recruiting N/A to 65 years.
- Allogeneic Stem Cell Transplantation Followed By Adoptive Immunotherapy for Patients With Relapsed and Refractory Hodgkin's Disease.
Gemcitabine; Fludarabine; Melphalan; Antithymocyte Globulin; Allogeneic Stem Cell Infusion; Tacrolimus; Filgrastim (G-CSF); Methotrexate

CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Lo Clinical Trial using Everolimus and Rituximab

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas and Hodgkin's Lymphoma.
Everolimus and Rituximab

Graft Versus Host Disease, Leukemia, or Lymphoma Clinical Trial using rituximab; fludarabine phosphate; melphalan; sirolimus; tacrolimus; allogeneic hematopoietic stem cell transplantation; indium In 111 ibritumomab tiuxetan; yttrium Y 90 ibritumomab tiuxetan; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years to 69 years.
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan.
rituximab; fludarabine phosphate; melphalan; sirolimus; tacrolimus; allogeneic hematopoietic stem cell transplantation; indium In 111 ibritumomab tiuxetan; yttrium Y 90 ibritumomab tiuxetan; laboratory biomarker analysis

Hodgkins Disease Clinical Trial using Proton

Indiana University - Recruiting 10 years to 30 years.
- Breast-Sparing Proton Therapy for Hodgkin's Disease in Young Females Demonstrated By Positron Emission Tomograpy (PET) Scanning: A Pilot Study.
Proton

Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disea Clinical Trial using Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 74 years.
- Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders.
Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphom Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol.

Hodgkin Disease, or Hodgkin Lymphoma Clinical Trial using Filgrastim; Plerixafor; Yttrium-Daclizumab (CHX-A Daclizumab); Carmustine; Etoposide; Cytarabine; Melphalan; Ca(2+)-DTPA

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I/II Trial of Yttrium-90-labeled Daclizumab (Anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin s Lymphoma.
Filgrastim; Plerixafor; Yttrium-Daclizumab (CHX-A Daclizumab); Carmustine; Etoposide; Cytarabine; Melphalan; Ca(2+)-DTPA

Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or Hodgkin Disease Clinical Trial using Antigen Escalation Stage; Dose escalation study of T cells

Baylor College of Medicine - Recruiting N/A or older.
- Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma.
Antigen Escalation Stage; Dose escalation study of T cells

Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Di Clinical Trial using LMP, BARF1 & EBNA1 specific CTLs: A; LMP, BARF1 & EBNA1 specific CTLs : B

Baylor College of Medicine - Recruiting N/A or older.
- Administration of Rapidly Generated LMP, BARF1 And EBNA1 Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma.
LMP, BARF1 & EBNA1 specific CTLs: A; LMP, BARF1 & EBNA1 specific CTLs : B

Lymphoma, Non-Hodgkin, or Hodgkin's Disease Clinical Trial

Stanford University - Recruiting 18 years or older.
- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease.

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML); Clinical Trial using CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Columbia University - Recruiting N/A to 22 years.
- CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

Lymphoma, or Hodgkin Disease Clinical Trial using tumor tissue aspiration; phlebotomy

Stanford University - Recruiting N/A to 21 years.
- Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy.
tumor tissue aspiration; phlebotomy

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Lymphoma, Non-Hodgkin, or Hodgkin Disease Clinical Trial using Abraxane

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma.
Abraxane

Leukemia, or Lymphoma Clinical Trial using valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL.
valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

Hodgkin's Disease, or Non-Hodgkin's Lymphoma Clinical Trial using Vorinostat (SAHA) and Niacinamide; Vorinostat, Niacinamide and Etoposide

Columbia University - Recruiting 18 years or older.
- Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies.
Vorinostat (SAHA) and Niacinamide; Vorinostat, Niacinamide and Etoposide

Hodgkin Disease Clinical Trial using Lenalidomide

Washington University School of Medicine - Recruiting 18 years or older.
- A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma.
Lenalidomide

Lymphoma Clinical Trial using biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting N/A or older.
- Hodgkin Disease (HD) Banking Study.
biologic sample preservation procedure

Hodgkin Disease, or Lymphoma, Non-Hodgkin Clinical Trial using Database

King Faisal Specialist Hospital & Research Center - Recruiting 14 years to 85 years.
- Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases.
Database